0001628280-26-031742
SEC filingQ1 revenue accelerated 30.1% to $68.4M, driving gross profit up 35.8% to $49.3M at 72.0% margin while narrowing operating loss 37.0% to -$8.1M, supported by strong cash collections and disciplined capex.
Revenue increased 30.1% to $68.4 million in Q1 FY2026 from $52.6 million in the prior year quarter. This acceleration underscores the company's focus on growing its existing commercial business with MACI and Epicel, as highlighted in management commentary since their 2014 acquisition. The growth provides a foundation for scaling operations while investing in commercialization.
Operating loss narrowed 37.0% to -$8.1 million from -$12.8 million, with operating margin improving to -11.8%. The increase in selling, general and administrative expenses reflects higher headcount and employee expenses, including MACI sales force expansion, and facility costs for the new Burlington, Massachusetts location. These investments signal commercial ambition to broaden market reach, such as through the MACI Arthro launch expanding the target surgeon base, even as they pressure near-term operating results. Revenue growth outpacing these expense increases demonstrates effective resource allocation.
Net income improved 44.0% to -$6.3 million, with diluted EPS of -$0.12 versus -$0.23. Higher other income from interest on marketable securities and money market funds contributed to the loss narrowing. Management's emphasis on revenue growth through commercial investments positions Vericel to navigate future results influenced by factors noted in the prior 10-K, maintaining focus on execution and liquidity.